Turnover: ()

Country: France

Biotechnology, drug development

News

Soda disease: Inventiva expands in Asia | Impact of soda consumption in Asia. 06/10/2023

  • Inventiva was founded 11 years ago.
  • It has 115 employees, including some 50 researchers.
  • It has been listed on the stock exchange since 2017 and on Nasdaq since 2020.
  • The global market for their field of activity (treatment of "soda disease") is estimated at between $15 and $30 billion, and the disease affects 10% of the adult population in the United States.
  • The partnership signed with Sino Biopharm in September 2022 resulted in an initial payment of $12 million, with the potential to reach up to $290 million in milestone payments.
  • The contract recently signed with Hepalys Pharma for Japan and South Korea provides for an initial receipt of $10 million for a total of up to $231 million in milestone payments, plus royalties of 10% to 20% on sales.
  • Inventiva holds a 30% stake in Hepalys Pharma.

Financial Data

DUNS: 537530255

Legal Name: INVENTIVA

Address: 50 RUE DE DIJON , 21121 DAIX

Capital: 421 342 EUR


Financial Data:

Year Turnover (€) Net Profit (€) Fiscal Year End Fiscal Year Duration
2020 372 000 EUR -31 578 000 EUR 31/12/2020 12
2019 4 777 870 EUR -30 802 920 EUR 31/12/2019 12
2018 3 303 010 EUR -31 956 860 EUR 31/12/2018 12
2017 6 520 820 EUR -10 135 460 EUR 31/12/2017 12
2016 9 445 640 EUR 5 595 740 EUR 31/12/2016 12

Company Managers:

Position First Name Last Name Age Linkedin
Directeur général Frédéric CREN 58

> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)

 

Ask Sector-GPT  

Sector-GPT est la première IA dédiée aux informations sectorielles.